[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Fanconi Anemia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 50 pages | ID: F4B33687DEECEN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Fanconi Anemia PIPELINE HIGHLIGHTS
Fanconi Anemia is one of the widely researched conditions during 2020 with 6 companies actively focusing on realizing pipeline’s potential. Development of Fanconi Anemia medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Fanconi Anemia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Fanconi Anemia.

Good progress is anticipated during 2020 and 2021 with Fanconi Anemia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Fanconi Anemia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Fanconi Anemia DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Fanconi Anemia pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Fanconi Anemia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Fanconi Anemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Fanconi Anemia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Fanconi Anemia DRUG PROFILES
Fanconi Anemia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Fanconi Anemia COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Fanconi Anemia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Fanconi Anemia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 6 Fanconi Anemia companies including company overview, key snapshot, contact information, and their strategies on accelerating Fanconi Anemia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Elixirgen Therapeutics LLC, Foresee Pharmaceuticals Co Ltd, Genethon SA, Novartis AG, Rimedion Inc, Rocket Pharmaceuticals Inc

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Fanconi Anemia
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO FANCONI ANEMIA

1.1 Fanconi Anemia- Disease overview
1.2 Fanconi Anemia- Market Size
1.3 Fanconi Anemia- Companies Involved

2. FANCONI ANEMIA PIPELINE SNAPSHOT- 2020

2.1 Fanconi Anemia Pipeline by Phase
2.2 Fanconi Anemia Pipeline by Mechanism of Action
2.3 Fanconi Anemia Pipeline by Route of Administration
2.4 Fanconi Anemia Pipeline- New Molecular Entities
2.5 Fanconi Anemia Pipeline- Orphan Drug Designation/ Special Designation

3. FANCONI ANEMIA DRUG PROFILES

3.1 Current Status
3.2 Fanconi Anemia Drug Snapshot
3.3 Fanconi Anemia Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Elixirgen Therapeutics LLC Fanconi Anemia Pipeline Insights and Clinical Trials
4.2 Foresee Pharmaceuticals Co Ltd Fanconi Anemia Pipeline Insights and Clinical Trials
4.3 Genethon SA Fanconi Anemia Pipeline Insights and Clinical Trials
4.4 Novartis AG Fanconi Anemia Pipeline Insights and Clinical Trials
4.5 Rimedion Inc Fanconi Anemia Pipeline Insights and Clinical Trials
4.6 Rocket Pharmaceuticals Inc Fanconi Anemia Pipeline Insights and Clinical Trials

5. FANCONI ANEMIA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications